Ipsogen, New Haven Conn, a molecular diagnostic company, has inked a pilot agreement with pharmaceutical provider AstraZeneca, Wilmington, Del, to evaluate molecular services and products in cancer research.

Ipsogen will provide AstraZeneca with JAK2-based products for initial evaluation, and the company will conduct quantitative analysis in its Marseille labs on samples provided by AstraZeneca.

The study will help determine the viability of a test that could potentially be used by AstraZeneca in future clinical trials.

Ipsogen is the exclusive worldwide licensee of the intellectual property on JAK2 V617F mutation discovered by a team from Inserm, France. Inserm is a public organization dedicated to biological, medical, and public health research.